Valuation: Access Bio, Inc.

Market Cap 83.19B 60.08M 51.49M 48.24M 44.07M 83.16M 5.73B 83.98M 569M 222M 2.89B 226M 221M 9.57B P/E 2024
-511x
P/E 2025 -1.63x
Enterprise Value -277B -200M -171M -161M -147M -277M -19.07B -280M -1.89B -738M -9.62B -751M -735M -31.86B EV / Sales 2024
-1.83x
EV / Sales 2025 -7.25x
Free-Float
99%
Yield 2024 *
-
Yield 2025 -
1 day-1.66%
1 week+3.73%
Current month+10.00%
1 month+5.11%
3 months-31.65%
6 months-32.62%
Current year-37.76%
1 week 2,190
Extreme 2190
2,725
1 month 1,945
Extreme 1945
2,725
Current year 1,945
Extreme 1945
4,705
1 year 1,945
Extreme 1945
5,280
3 years 1,945
Extreme 1945
14,340
5 years 1,945
Extreme 1945
23,850
10 years 1,580
Extreme 1580
62,900
Manager TitleAgeSince
Chief Executive Officer 62 2002-01-31
Director TitleAgeSince
Chairman 62 2002-01-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%+3.73%-55.04%-70.62% 60.08M
+1.07%+3.00%+166.52%+330.71% 22.13B
-0.66%+2.60%-37.19%-22.00% 10.37B
+1.44%+16.34%+359.99%+35.14% 8.43B
+7.19%+33.57%-27.21% - 7.92B
+0.07%+0.61%+79.61%+51.98% 6.58B
-0.12%-3.82%-14.67%-10.78% 6.01B
-0.08%+3.26%-16.05%-19.84% 4.39B
-2.48%-11.72%+56.86%+98.49% 4.09B
+0.26%-0.55%-19.52%-24.57% 2.91B
Average +0.51%+5.74%+49.33%+40.95% 7.29B
Weighted average by Cap. +1.04%+6.49%+91.35%+121.67%

Financials

2024 2025
Net sales 112B 81.23M 69.61M 65.22M 59.58M 112M 7.74B 114M 769M 299M 3.91B 305M 298M 12.94B 31.26B 22.57M 19.34M 18.13M 16.56M 31.25M 2.15B 31.56M 214M 83.23M 1.09B 84.76M 82.92M 3.6B
Net income -348M -251K -215K -202K -184K -347K -23.93M -351K -2.38M -926K -12.08M -943K -922K -39.99M -82.12B -59.31M -50.82M -47.62M -43.5M -82.1M -5.65B -82.91M -562M -219M -2.85B -223M -218M -9.45B
Net Debt -389B -281M -241M -226M -206M -389M -26.78B -393M -2.66B -1.04B -13.51B -1.05B -1.03B -44.74B -360B -260M -223M -209M -191M -360M -24.8B -364M -2.46B -959M -12.51B -977M -955M -41.44B
Logo Access Bio, Inc.
Access Bio, Inc. focuses on preventing and diagnosing infectious diseases early through research, development, and manufacturing of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. The Company also launched diagnostic products, including tests for Coronavirus Disease 2019 (COVID-19), Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, dengue fever, influenza, and strep. The Company has commercialized products to combat malaria and other diseases. The Company’s product lineup includes COVID-19 Detection Kits -These kits assess the current or past presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Rapid Diagnostic Tests (RDTs) - RDTs are used for preliminary diagnosis or emergency medical screening in facilities with limited resources; Analyzers - Designed to measure various chemicals and characteristics in biological samples; and Molecular Diagnostics - These are used to analyze biological markers in the genome and proteome.
Employees
101
Date Price Change Volume
26-08-25 ₩2,365.00 -1.66% 221,830
26-08-24 ₩2,405.00 +6.65% 1,271,747
26-08-21 ₩2,255.00 -2.80% 37,812
26-08-20 ₩2,320.00 +5.69% 53,888
26-08-19 ₩2,195.00 -3.73% 18,277
  1. Stock Market
  2. Stocks
  3. A950130 Stock